AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25970667
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity intervention lasting 30 min over one academic year, led by preschool teachers with educational components for parents and teachers.
Trial: 15792142
Drug: Pronoran (piribedil)
RxNorm normalized name: piribedil
DrugBank: Piribedil (DB12478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pronoran (piribedil) 50 mg per day for 30 days
Trial: 15792142
Drug: Pronoran (piribedil)
RxNorm normalized name: piribedil
DrugBank: Piribedil (DB12478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pronoran (piribedil) 50 mg per day for 90 days
Trial: 7589011
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg day‐1)
Trial: 1771612
Drug: Concentrated ethylester
RxNorm normalized name: Ethylester kyseliny karbaminove
DrugBank: Urethane (DB04827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ethylester compound of n‐3 fatty acids (3.15 g EPA and 1.89 g DHA daily)
Trial: 1771612
Drug: Concentrated ethylester
RxNorm normalized name: Ethylester kyseliny karbaminove
DrugBank: Urethane (DB04827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ethylester compound of n‐3 fatty acids
Trial: 1771612
Drug: Concentrated ethylester
RxNorm normalized name: Ethylester kyseliny karbaminove
DrugBank: Urethane (DB04827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ethylester compound of n‐3 fatty acids and Corn oil (control)
Trial: 6751736
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine hydrochloride (50 mg three times daily)
Trial: 26544055
Drug: Alternative hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative hydration system (2 glucose/electrolyte solutions - 'two bag system')
Trial: 26544055
Drug: Traditional hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional hydration system (1 glucose/electrolyte solution)
Trial: 7805982
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of color Doppler and CA 125 or morphological assessments
Trial: 12063985
Drug: Interferon-alpha-2b plus
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy
Trial: 2672898
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% bupivacaine with epinephrine, 5 micrograms/ml
Trial: 2672898
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml preservative-free saline
Trial: 786663
Drug: Prorenoate potassium
RxNorm normalized name: Propanoic acid
DrugBank: Propanoic acid (DB03766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prorenoate potassium 45 mg
Trial: 7066166
Drug: Spironolactone 100
RxNorm normalized name: spironolactone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 100 mg
Trial: 18544992
Drug: Taxotere plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxotere plus prednisolone (30 mg/m2 weekly during 5 of 6 weeks + prednisolone 5 mg orally twice daily)
Trial: 18544992
Drug: Prednisolone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (5 mg orally twice daily)
Trial: 15975314
Drug: ABCBS herbs
RxNorm normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABCBS herbs orally taken in addition to conventional treatment
Trial: 15975314
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with western medicine (WM) and Salvia injection
Trial: 8591941
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg single dose
Trial: 25866384
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 10 sessions before surgery
Trial: 17416113
Drug: Diamicron 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamicron 80 mg tablet from Servier (Ireland) Industries Limited (Control)
Trial: 9661037
Drug: Itraconazole solution
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole solution (200 mg)
Trial: 9661037
Drug: Hydroxyitraconazole solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyitraconazole solution (200 mg)
Trial: 9661037
Drug: Capsule formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulations (200 mg)
Trial: 1489075
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia induced with thiopentone 2‐5 mg/kg, continued with low‐dose fentanyl (1‐2 micrograms/kg), oxygen/nitrous oxide/isoflurane (30/70/0.1‐0.5%), vecuronium
Trial: 2860271
Drug: Intrapleural Corynebacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural Corynebacterium parvum 7 mg
Trial: 29526416
Drug: CMR-LGE quantification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMR-LGE quantification using a threshold of 8SD for peak TnI>50ng/mL
Trial: 29526416
Drug: CMR-LGE quantification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMR-LGE quantification using a threshold of 4SD for peak TnI>95ng/mL
Trial: 24739799
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg twice daily
Trial: 7822649
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection system for delivering local anesthetic
Trial: 30763142
Drug: Darolutamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darolutamide (600 mg [two 300-mg tablets] twice daily)
Trial: 26795844
Drug: 20 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg/kg palonosetron
Trial: 28941006
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 150 μg/kg ondansetron
Trial: 23017464
Drug: Savoury food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savoury food items (e.g., mashed potatoes, tortilla chips)
Trial: 23017464
Drug: Savoury food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savoury food items (e.g., canned tomatoes, tortilla chips)
Trial: 21871095
Drug: Robotic arm
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic arm therapy
Trial: 9124993
Drug: Piperacillin/tazobactam (P/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (P/T) monotherapy, daily dose of 12/1.5 g for an average of 10 days
Trial: 8354894
Drug: Interleukin-1 alpha
RxNorm normalized name: interleukin-1 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-1 alpha (IL-1 alpha) infusion
Trial: 3730024
Drug: Intravenous ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ifosfamide (Holoxan) at 1 g/m2
Trial: 25992488
Drug: Indapamide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (1 mg/day)
Trial: 23084000
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with DCAD of 50 mEq/kg DM + 25(OH)D (3 mg/steer per day)
Trial: 23084000
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with DCAD of 150 mEq/kg DM + 25(OH)D (3 mg/steer per day)
Trial: 15515745
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone (thyroxine) replacement
Trial: 31926085
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment in children
Trial: 14734877
Drug: G‐ORS
RxNorm normalized name: Oral Rehydration Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐ORS
Trial: 28192629
Drug: Co-trimoxazole (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (960 mg twice daily)
Trial: 15232813
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block plus IV PCA morphine (G1)
Trial: 15232813
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine and fentanyl PCA infusion (G2)
Trial: 8996133
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg twice daily) in patients who vomited in the first 24 hours
Trial: 8996133
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg every 6 hours) in patients who vomited in the first 24 hours
Trial: 27522871
Drug: Self-reported drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported drug use (TLFB)
Trial: 24399455
Drug: Magnetic field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic field therapy (2 Hz) applied to each hip region for 20 min, n = 35
Trial: 24399455
Drug: Placebo magnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo magnetic field therapy applied to each hip region for 20 min, n = 31
Trial: 24074502
Drug: Dexamethasone 30
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 30 mg perioperatively
Trial: 18853973
Drug: Adalimumab maintenance
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab maintenance therapy (40 mg every other week)
Trial: 18853973
Drug: Adalimumab maintenance
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab maintenance therapy (40 mg weekly)
Trial: 18853973
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after induction therapy
Trial: 15994121
Drug: Partial sleep
RxNorm normalized name: SOY OIL,PARTIALLY HYDROGENATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial sleep deprivation therapy combined with sertraline (LPSD group)
Trial: 15994121
Drug: Sertraline monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline monotherapy (Control group)
Trial: 12448241
Drug: Amoxicillin/clavulanate single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate single-dose regimen
Trial: 2794058
Drug: MK-329 10
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-329 10 mg
Trial: 14982
Drug: Flunisolide (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide (active drug)
Trial: 14522725
Drug: High physical
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High physical activity (HPA) treatment with an energy expenditure (EE) goal of 2500 kcal/wk
Trial: 14522725
Drug: Standard behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavior therapy (SBT) for obesity with an EE goal of 1000 kcal/wk
Trial: 31601587
Drug: Multicomponent self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent self-management intervention for opioid tapering
Trial: 26942358
Drug: Quickstart group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quickstart group (etonogestrel implants with mifepristone)
Trial: 26942358
Drug: Afterstart group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afterstart group (etonogestrel implants after abortion)
Trial: 25122041
Drug: tizanidine 4
RxNorm normalized name: tizanidine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tizanidine 4 mg
Trial: 22997780
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (Sodium Nitroprusside, Mannite, etc.)
Trial: 24796048
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group
Trial: 17483139
Drug: Weekly support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly support
Trial: 16350718
Drug: Soluble VEGF
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Soluble VEGF receptor concentrations in patients with benign and malignant thyroid tumors
Trial: 12101195
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of neoadjuvant hormonal treatment (NHT)
Trial: 10438352
Drug: Indinavir, zidovudine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir, zidovudine, and lamivudine (triple therapy)
Trial: 2370328
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate cream applied for 0.5 hours
Trial: 2370328
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate cream applied for 1.0 hours
Trial: 2370328
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate cream applied for 1.5 hours
Trial: 2370328
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate cream applied for 16.0 hours
Trial: 2370328
Drug: 0.05% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% fluocinonide cream applied for 16 hours
Trial: 29172680
Drug: DR/ER-MPH (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DR/ER-MPH (40-80 mg/day)
Trial: 19956761
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g)
Trial: 21946903
Drug: Survivors using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survivors using hot flash treatments
Trial: 14767813
Drug: Ganciclovir implant
RxNorm normalized name: ganciclovir Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir implant plus oral placebo
Trial: 9431375
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir alone
Trial: 10194235
Drug: Ganciclovir implant
RxNorm normalized name: ganciclovir Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir implant plus oral ganciclovir (4.5 g daily)
Trial: 10194235
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir or intravenous ganciclovir
Trial: 7582042
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment studies
Trial: 2253196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (1 mg/m2 daily)
Trial: 2253196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (3 mg/m2 daily)
Trial: 2253196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (8 mg/m2 daily)
Trial: 2253196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (12 mg/m2 daily)
Trial: 2253196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rhIL-2 and R24
Trial: 7114512
Drug: Nicergoline (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (0.3 mg/kg bolus, 0.8 mg/kg/h maintenance)
Trial: 27768397
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) supplementation (0.3 g・kg‐1・d‐1 for 5 days followed by 0.1 g・kg‐1・d‐1 for 23 days; n = 9)
Trial: 26375599
Drug: Methylene blue-mediated
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue-mediated photodynamic inactivation followed by low-laser therapy
Trial: 8290882
Drug: Miconazole gel
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole gel
Trial: 7970483
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg/day) alone
Trial: 7970483
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day continuously)
Trial: 7970483
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day for last 14 days of each cycle)
Trial: 7970483
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg/day) + MPA (10.0 mg/day for last 14 days of each cycle)
Trial: 1105487
Drug: prazosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prazosin plus one or more other antihypertensive drugs
Trial: 28431564
Drug: Capsaicin 8%
RxNorm normalized name: CAPSAICIN 8% PATCH KIT,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin 8% patch
Trial: 14693607
Drug: Rofecoxib oral
RxNorm normalized name: rofecoxib Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib oral suspension 25 mg (Group B)
Trial: 12491077
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (JCOG 8801 study)
Trial: 2223157
Drug: Bestatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin treatment in adenocarcinoma
Trial: 349961
Drug: Proteinase inhibiting
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proteinase inhibiting agents and glucagon
Trial: 28247635
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy only
Trial: 21334033
Drug: Oral beta-blockers
RxNorm normalized name: beta carotene Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta-blockers
Trial: 14994390
Drug: Etodolac (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (300 or 1000 mg daily)
Trial: 7648827
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no supplementary insulin)
Trial: 7648827
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin (1.8U over 15 min, extended over 30 min)
Trial: 30442551
Drug: Midazolam 15mg
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 15mg (oral)
Trial: 20178033
Drug: Citalopram (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (selective serotonin reuptake inhibitor), duration: 12 weeks
Trial: 11907350
Drug: Currently available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Currently available IBD therapies and those used in clinical trials for ulcerative colitis.
Trial: 8006126
Drug: Artificial cycle
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial cycle (Goserelin 3.6 mg s.c. followed by hormone replacement therapy)
Trial: 22647413
Drug: Amlodipine/valsartan 5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 5/160 mg SPC
Trial: 24423017
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (LAI)